Background/Aims: The objective of this study is to evaluate the hypouricemic and nephroprotective effects of an active fraction from Polyrhachis vicina Roger (AFPR) in potassium oxonate-induced hyperuricemic rats. Methods: Hyperuricemia was induced by potassium oxonate in male rats. AFPR was orally administered to hyperuricemic rats for 12 consecutive weeks. Serum, liver and kidney samples were collected for effects and mechanism analysis. The levels of serum uric acid (SUA) were measured by the phosphotungstic acid method, xanthine oxidase (XOD) activity in the hepatic and serum samples were measured by ultraviolet spectrophotometry, serum levels of interleukin-1 (IL-1β), interleukin-1 (IL-6) and tumor necrosis factor-α (TNF-α) were measured by ELISA, the levels of serum creatinine (SCr), blood urea nitrogen (BUN), super oxide dismutase (SOD) and malondialdehyde (MDA) in serum were determined by colorimetric method. Protein expression of renal URAT1, GLUT9, and OAT1 were analyzed by Western blot. Results: AFPR significantly decreased the levels of SUA, serum and hepatic XOD, SCr, BUN, and MDA as well as increased SOD. In addition, AFPR treatment significantly reduced the levels of proinflammatory cytokines in serum, including IL-1β, IL-6 and TNF-α. Moreover, we found the significant decrease in protein expression of URAT1 and GLUT9, and the significant increase in protein expression of OAT1 in the kidney in AFPR treated groups compared to the model groups of hyperuricemia. Conclusion: These findings suggest that AFPR has anti-hyperuricemic activity attributed to the inhibition of uric acid generation in the liver and probably to the enhancement of urate excretion in the kidney, and possess nephroprotective effect in hyperuricemic rats due to its anti-inflammatory and antioxidant activities.
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Introduction
Hyperuricemia is a metabolic disease characterized by high uric acid levels in the blood [1] which increased risk of hypertension, renal, diabetes and cardiovascular diseases [2] [3] [4] . Uric acid is the end product of purine degradation and its homeostasis depends on the balance between production and elimination. Studies showed that decreased urate clearances were found in mostly hyperuricemic patients, indicating the important role of renal urate handling [5] through the complex transepithelial transport systems that promote both reabsorption and secretion of urate [6] [7] [8] . The urate reabsorption pathway includes the apical urate/anion exchanger URAT1 [6, 9] , basolateral glucose transporter9 (GLUT9) [10] [11] [12] , and the secretion pathway involves the basolateral urate/dicarboxylate exchangers OAT1 [11, 13] . Xanthine oxidase (XOD) is the key enzyme participating in oxidation of hypoxanthine to xanthine and then to uric acid [14] . Therefore, the treatment strategy for hyperuricemia mainly focuses on decreasing the in vivo production of uric acid by xanthine oxidoreductase inhibitors such as allopurinol, febuxostat and topiroxostat and promoting increased excretion of uric acid in the urine by using uricosuric agents such as probenecid, benzbromarone and lesinurd. Though urate-lowering agents are currently available, treatment failures were reported in 25-50% of patients with hyperuricemia due to suboptimal response to drugs at the recommended dose, failure to tolerate adverse events or contraindications to their use [15] . Allopurinol is sometimes associated with gastrointestinal symptoms, rash, Steven-Johnson's syndrome [16] , chronic kidney disease [17, 18] and allopurinol hypersensitivity syndrome (AHS) [19] . Its rare side effect of AHS is associated with death in ~ 27% of the patients who develop AHS [20] . Drug interactions are another limitation to the use of allopurinol [21, 22] . Cardiovascular events were reported in febuxostat treatment [23] and cost is another limiting factor to its use [24] . Probenecid, benzbromarone and sulfinpyrazone are associated with increased risk of urate calculi in the kidney [25] . Hepatotoxicity has been a big concern with benzbromarone [26] . Drug interactions of probenecid with NSAIDS, penicillin, heparin, mycophenolate, methotrexate and zidovudine are documented [27] [28] [29] [30] [31] . Therefore, the searches for more effective and less toxic agents against hyperuricemia are highly warranted. Natural products devoid of such disadvantages offer a great opportunity [32] [33] [34] [35] [36] [37] .
Polyrhachis vicina Roger, known as Chinese black ant, was demonstrated to possess extensive pharmacological action, such as anti-rheumatic [38, 39] and anti-inflammatory [40] effects and has been widely used as folk medicine and health care food against hyperuricemia and gout [41, 42] . Our previous studies revealed that an active fraction extracted from Polyrhachis vicina Roger (AFPR) showed obvious anti-inflammatory and antioxidant activities [43] and markedly inhibited hyperuricemia that was induced by hypoxanthine in mice [44] . GC-MS analysis showed that unsaturated fatty acids comprise 71.14% of the major components, with 60.77% of octadecenoic acid, 9.31% of heptadecenoic acid and 1.06% of leinoleic acid, and saturated fatty comprise 25.04% of the components in AFPR [44] . The study identifying and purifying the active extract present in AFPR is ongoing. The present study was to investigate the effects of AFPR on hyperuricemia induced by potassium oxonate in rats, and the levels of serum and hepatic XOD and renal protein expression of the transporters participating in the excretion of urate acid, including URAT1, GLUT9 and OAT1, were analyzed; the levels of SCr, BUN, renal SOD activities and levels of renal MDA were detected to evaluate the toxicity of AFPR, the levels of serum inflammatory cytokines including IL-1β, IL-6 and TNF-α were also detected to evaluate its anti-inflammatory activity.
Establishment of a hyperuricemic rat model and drug administration
In the present study, an experimental model of hyperuricemia induced by potassium oxonate was adopted according to Lemos Lima Rde C et al [46] . with modifications. Fifty male rats were randomly divided into 5 experimental groups (n=10) that were fasted for 1 h before drug administration. Potassium oxonate was administered to the rats of groups 2-5 (650 mg/kg, ig) at 8:00 am, and drug treatments were given by gavage 4 h after potassium oxonate administration daily for a consecutive 12 weeks of experiment. Groups 1 (normal control group) and 2 (hyperuricemia model group) received vehicle alone. Group 3 was treated with allopurinol (20 mg/kg). Groups 4 and 5 were treated with AFPR at doses of 15.60 and 3.65 mg/ kg body weight, respectively.
Blood, hepatic and kidney tissue sample collection
On the 28th day (the last day of the 4th week), 56th day (the last day of the 8th week), and 84th day (the last day of the 12th week), 1 h after drug administration, blood samples were collected from the tail vein. These samples were maintained at room temperature until blood coagulation and then centrifuged at 1500×g for 5 min. Supernatants were collected and centrifuged at 3000×g for 10 min to obtain serum. All animals were given pentobarbital sodium (50 mg/kg, intraperitoneal injection) and then sacrificed on the 84th day. Liver samples were quickly dissected on ice and homogenized in 9× volumes of 80 mM sodium pyrophosphate buffer (pH 7.4). The homogenate was centrifuged at 3000×g for 10 min, and the supernatant was used for the XOD assay. In addition, the cortex of the kidneys was quickly and precisely separated on an ice-plate and kept at -80°C for protein analysis.
Determination of SUA
The SUA levels at 4, 8, and 12 weeks after drug administration were measured to determine the successful establishment of the hyperuricemia model and therapeutic effects of AFPR by the phosphotungstic acid method [47] , according to the manufacturer's instruction (Jiancheng Institute of Biotechnology, Nanjing, China).
Measurement of serum and hepatic XOD activity
The XOD activity in the hepatic and final serum samples were measured using XOD assay kit (Jiancheng Institute of Biotechnology, Nanjing, China) following the manufacturer's instruction.
Analysis of urate transporter-related protein expression in kidney tissues
Protein extraction of kidney and Western blot analyses for renal URAT1, GLUT9, and OAT1 were adopted according to a previous study [48] , with modification. The primary antibodies (SaiChi Biotech, Beijing, China)) used were as follows: anti-URAT1 (1:1000), anti-GLUT9 (1: 1000), anti-OAT1 (1: 1000), anti-GAPDH (1: 1000), respectively. Immunoreactive bands were quantified via a Bio-Rad VersaDoc imaging system model 5000 with Bio-Rad Quantity One software (Bio-Rad, Hercules, CA). Relative quantitation for Western blot analysis was calculated after the normalization to the amount of GAPDH.
tissue was instantly fixed in 10% phosphate buffered formalin (Sigma-Aldrich, St. Louis, Missouri, USA), processed by routine histology procedures, embedded in paraffin, sectioned in 5 μm pieces and mounted on a slide. The samples were stained with hematoxylin and eosin (H&E) (Sigma-Aldrich, St. Louis, Missouri, USA) for histopathological examination.
Statistical analysis
All data are expressed as the mean values±S.E.M. Statistical analysis was performed using one-way analysis of variance (ANOVA), followed by the LSD post-hoc test. P values <0.05 were considered statistically significant.
Results
Acute toxicology test of AFPR
As shown in Table 1 , AFPR at two doses of 285 mg/kg and 2000mg/kg, respectively, administrated to male rats, caused no significant effects on their behavioral, neurologic, and autonomic profiles during the 14 days observation periods. No mortality was observed for up to 14 days of monitoring. The value of the lethal dose at 50% of the extract in rats was estimated to be more than 2000mg/kg, which is equivalent to around 37 times the clinical dose.
AFPR decreased the level of SUA in potassium oxonate-induced hyperuricemic rats
As shown in Fig. 1 , the SUA level in the model group was higher than that in the normal group (p<0.01) 8 and 12 weeks after potassium oxonate administration, indicating the successful establishment of the hyperuricemia model. By contrast, treatments with AFPR (15.60 mg/kg and 3.65mg/kg) and allopurinol (20 mg/kg) significantly lowered the SUA level in hyperuricemic rats (p<0.01 or p<0.05). The levels of serum uric acid in 24 hours following the administration of potassium oxonate are fluctuating, but the difference showed no statistical significance.
AFPR inhibited XOD activity in hyperuricemic rats
XOD is a key enzyme in uric acid production. In this experiment, the levels of serum and hepatic XOD activities in the hyperuricemic model group were higher than those in the normal group (p< 0.01). Allopurinol, a XOD inhibitor, significantly suppressed the serum and hepatic XOD activities in hyperuricemic rats (p<0.05 or p<0.01). Similarly, AFPR (15.60 mg/kg and 3.65 mg/kg) attenuated the elevated serum and hepatic XOD activities, which were induced by potassium oxonate administration (p < 0.05) (Fig. 2) .
AFPR regulated the protein levels of renal GLUT9, URAT1 and OAT1 in hyperuricemic rats
To investigate the effects of AFPR on urate excretion, the protein expression of urate transporters was evaluated. As expected, significantly elevated levels of renal GLUT9 and URAT1 and depressed levels of OAT1 were found in potassium oxonate-induced hyperuricemic rats compared to the normal group (P<0.01). Allopurinol (20 mg/kg) significantly down-regulated the expression of renal GLUT9 and URAT1 and up-regulated the expression of renal OAT1 in hyperuricemic rats (P<0.01 or P<0.05). Similarly, AFPR (15.60 mg/kg and 3.65 mg/kg) markedly decreased the potassium oxonate-induced elevation in renal GLUT9 and URAT1 (p<0.01 or p<0.05) and increased the depressed renal OAT1 levels (p<0.05) (Fig. 3) .
AFPR reduced the levels of serum IL-1β, IL-6 and TNF-α in hyperuricemic rats
Hyperuricemia stimulated inflammatory mediators and caused an inflammatory reaction. The results of this experiment showed that the serum IL-1β, IL-6 and TNF-α levels in hyperuricemia rats were significantly higher than those in the normal group (p<0.05). Allopurinol (20 mg/kg) and AFPR (15.60 mg/kg and 3.65 mg/kg) significantly reduced the serum IL-1β, IL-6 and TNF-α levels of hyperuricemia rats (p<0.05) (Fig. 4) .
Oxidation resistance effect of AFPR in hyperuricemic rats
Hyperuricemia induced oxidative stress. To evaluate the oxidation resistance effect of AFPR, the serum SOD and MDA levels were determined. There were significant decreases in the serum SOD activities and significant increases in the serum MDA levels in hyperuricemic Fig. 2 . Effects of AFPR on XOD activities in the serum (A) and liver (B) in hyperuricemia rats. N=10 per group. ##p<0.01 compared with the normal group; *p<0.05 and **p<0.01 compared with the hyperuricemia model group.
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rats compared to those in the normal group (p<0.05). AFPR (15.60 mg/kg and 3.65 mg/kg), and allopurinol (20 mg/kg) significantly reversed the effects of potassium oxonate on the serum SOD activities and MDA content (p<0.05) (Fig. 5) .
Nephroprotective effect of AFPR in hyperuricemic rats
As shown in Fig. 6 , the serum levels of SCr and BUN of hyperuricemic rats were remarkably higher than those in the normal group. However, this trend was reversed following AFPR (15.60 mg/kg and 3.65 mg/kg) and allopurinol administration. In addition, histological analysis demonstrated that the brush border of epithelial cells remarkably disappeared and renal tubules shrank in hyperuricemic rats, whereas these pathologies were ameliorated to some degree after treatment with AFPR (15.60 mg/kg and 3.65 mg/kg) and allopurinol (20 mg/kg) administration (all p<0.05) (Fig. 7) . 
Discussion
Polyrhachis vicina Roger has been widely used as folk medicine against gout in minority areas of Southwest China, its activity of anti-gout and anti-hyperuricemia in model animals were verified in our previous study [43, 44] . However, the exact mechanism underpinning its efficacy is unclear. In the present study, we demonstrated that an active fraction from Polyrhachis vicina Roger (AFPR) reduced serum urate levels through suppressing OXD activities and regulating the expression abnormality of renal URAT1, GLUT9 and OAT1 directly or indirectly in hyperuricemic rats. Furthermore, AFPR was found to alleviate renal damage manifested by decreasing SCr and BUN level, reducing the serum IL-1β, IL-6 and TNF-α level, and/or decreasing serum SOD activities and increasing serum MDA levels in hyperuricemic rats. These findings confirm that AFPR exhibits hypouricemic and nephroprotective effects in hyperuricemic model of rats.
Potassium oxonate is most frequently employed to develop an animal model of hyperuricemia by inhibiting uricase that converts uric acid to allantoin [37, 49] . In the present study, serum uric acid levels were significantly increased 8 and 12 weeks after potassium oxonate administration, suggesting the successful establishment of hyperuricemia model. Elevated serum uric acid levels may contribute to chronic kidney disease development and progression [50] , indicating that in the present study hyperuricemia lead to shrinking of brush border shown in Fig.7 , instead of vice versa. In the present study, potassium oxonateinduced hyperuricemic rats developed the elevated levels of renal URAT1 and GLUT9 protein and depressed OTA1protein levels compared with normal-vehicle rats, which is consistent with the results of various studies [51] [52] [53] , but the mechanism involved is not clear.
The daily dose of Dried Polyrhachis vicina Rogers used as folk medicines in human is 0.2g/kg body weight, which is equivalent to 7.8mg AFPR/kg (0.2×3.9%/1000, the extraction amount of AFPR is 3.9% of Polyrhachis vicina Rogers). The dose of AFPR in rat (54.6mg AFPR/kg) is calculated by multiplying the dose in human (7.8mg AFPR/kg) by the conversion factor 7 [54] , in pilot study, we studied the hypouricemic effect of AFPR at various dose from 54.6mg AFPR/kg to 0mg AFPR/kg in rat including the two doses of 15.6 and 3.65mg/kg, which were calculated by dividing 54.6mg/kg by 3.5 and 15, respectively. We found in pilot study that AFPR at the various tested concentration showed hypouricemic effects to some extent. In consideration of cost, we used 15.6 and 3.65 mg/kg in the study.
XOD is the key enzyme in the process of purine production, which is translated into uric acid in the liver [14] . XOD inhibitors, such as allopurinol and febuxostat, are used to treat hyperuricemia. In the present study, AFPR demonstrated significant inhibition of serum and hepatic XOD in hyperuricemic rats, suggesting that inhibitory activity towards XOD might be one of anti-hyperuricemia mechanisms of AFPR. On the other hand, urate transporters in the proximal kidney are also involved in the pathogenesis of hyperuricemia [55] . URAT1 and GLUT9 are responsible for urate reabsorption, and OAT1 in the basolateral membranes of renal proximal tubules is responsible for primary renal urate secretion [9, 12, 13] . In the present study, we found the significant decrease in protein expression of URAT1 and GLUT9, and the significant increase in protein expression of OAT1 in the kidney in AFPR treated groups compared to the model groups of hyperuricemia. These results indicated that AFPR exerted its anti-hyperuricemic effect by inhibiting hepatic XOD activity, therefore leading to regulating the protein expression levels of renal URAT1, GLUT9 and OAT1, and/or directly by regulating the protein expression levels of renal URAT1, GLUT9 and OAT1, which are attributable to the reduction in urate production and enhancement of urate excretion, respectively.
Uric acid has been confirmed to stimulate inflammatory mediators and cause inflammatory reaction [56] . Many researchers have found that gout shares many pathogenetic features with other inflammatory disorders, such as a rapid increase in the production of proinflammatory cytokines, including IL-1β, IL-6 and TNF-α [57, 58] . The present study showed that AFPR significantly reduced the serum IL-1β, IL-6 and TNF-α level in hyperuricemia rats, suggesting that AFPR exerted its anti-inflammation efficacy to prevent hyperuricemia from developing into gout and other inflammatory disorders
It was reported that a high level of uric acid could induce oxidative stress, which was prone to causing organ damage [59] . As shown in Fig. 6 , there were significant decreases in the serum SOD activities and significant increases in the serum MDA levels in the hyperuricemia group compared with the normal group (P<0.05). AFPR significantly reversed the changes in the serum SOD activities and serum MDA levels in hyperuricemia rats, indicating that AFPR could inhibit oxidative stress by increasing the antioxidant enzyme activity, which might decrease the occurrence of hyperuricemia complications.
Hyperuricemia could increase the burden of the kidney and cause renal damage. In the present research, we found that the SCr and BUN levels, which are indicators of nephrotoxicity [60] , were significantly increased in the hyperuricemia group, whereas the increased SCr and BUN were significantly reduced following AFPR treatment. Moreover, the histopathological examination revealed that AFPR treatment markedly alleviated renal damage in hyperuricemia rats. The obtained results suggested that AFPR could significantly improve renal function [61] .
The acute toxicology testing of AFPR showed that oral administration of AFPR at the dose of 2000 mg/kg did not have toxic effects, and no death was found within 14 days of observation. The oral LD50 value of AFPR was greater than 2000 mg/kg bodyweight in mice, which is equivalent to around 37 times the clinical dose.
In summary, the present study first reported that AFPR was efficient in alleviating hyperuricemia underpinned by the mechanisms including as follows: i. reducing uric acid generation by inhibiting the hepatic and serum XOD activity to probably consequently leading to regulating the protein expression levels of renal URAT1, GLUT9 and OAT1, ii. probably directly regulating the protein expression levels of renal URAT1, GLUT9 and OAT1, consequently leading to increasing uric acid excretion, and decreasing uric acid reabsorption, respectively. Moreover, AFPR possess nephroprotective effect by attenuating the hyperuricemia-induced inflammatory reaction and oxidative stress. The present study showed that AFPR is worthy to be developed into an agent for hyperuricemia treatment.
Conclusion
AFPR is less toxic than other agents such as allopurinol [17, 18] , probenecid, benzbromarone and sulfinpyrazone [25] and may warrant further evaluation as a possible agent for treating hyperuricemia.
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